NCT06574984View on ClinicalTrials.gov

Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients

RecruitingOBSERVATIONAL
Enrollment

900

Participants

Timeline

Start Date

November 10, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions
Congenital Bleeding DisorderHaemophilia A
Interventions
DRUG

Turoctocog alfa

Turoctocog alfa was administered intravenously.

Trial Locations (5)

10001

ENROLLING_BY_INVITATION

National centre for Hamophilia, Baghdad

51001

NOT_YET_RECRUITING

Hilla Haemophilia centre, Hillah

56001

ENROLLING_BY_INVITATION

Karbala Haemophilia centre, Karbala

61001

NOT_YET_RECRUITING

Basrah Haemoplhilia centre, Basra

Unknown

RECRUITING

Novo Nordisk Investigational Site, Baghdad

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY